套细胞淋巴瘤,CAR-T细胞疗法 z-bo 2020-09-30 315

　　A one-year follow-up led by the University of Texas MD Anderson Cancer Center found that most patients with mantle cell lymphoma (mantle cell lymphoma) who are resistant to previous treatments can benefit from chimerism that targets CD19 antigen. Receptor (CAR) T cell (CAR-T) therapy has been proven to be sexual. This multicenter phase II clinical study (called ZUMA-2) reported that 93% of patients responded to this CAR-T cell therapy, while 67% of patients responded completely. Of the 28 patients initially treated, 43% were still in remission 2 years later. In CAR-T cell therapy, the patient's T cells are extracted through depletion of white blood cells, and genetically modified to express CAR molecules to help cancer cells attack. These genetically modified T cells were perfused in the same patient. Professor of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center

　　Michael Wang said: “For patients whose condition worsens after initial treatment, the treatment effect is usually insufficient. For patients with relapsed or refractory mantle cell lymphoma, if there is no curable treatment option, CAR-T cell therapy will be important and long-lasting Of. Shows clinical benefit."

　　Use standard therapy. Patients who get worse after treatment with Bruton tyrosine kinase inhibitor (BTKi) drugs can usually survive for more than 6 months. However, few patients are suitable for allogeneic stem cell transplantation. In this study, the median age of the patients was 65 years, and 84% of them were men. More than 80% of patients have stage IV mantle cell lymphoma, and half are diagnosed as moderate to high risk mantle cell lymphoma. The study reported grade 3 side effects, the most common being anemia and thrombocytopenia. Most patients will experience cytokine release syndrome, which is a common side effect of CAR-T cell therapy and is effectively controlled in all patients.

　　Wang said: "ZUMA-2 is the first multi-center phase II clinical trial using CAR-T cell therapy to treat relapsed/refractory mantle cell lymphoma. These mid-term efficacy and safety results are still in progress. However, the reported results (including controllable safety) indicate that this therapy is an effective and feasible treatment option for patients with relapsed or refractory mantle cell lymphoma.